

DR. DANIEL VITT

CEO, President and Director



Daniel Vitt, Ph.D., joined Immunic in January 2017. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. During his time at 4SC, Dr. Vitt was responsible for all research and development activities and successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline, addressing autoimmune, oncology and infectious diseases. Among these were resminostat, domatinostat and vidofludimus. In 2005, Dr. Vitt took 4SC AG public on the Frankfurt stock exchange.

During his tenure, Dr. Vitt also successfully negotiated and executed several key research and licensing agreements with biotechnology and pharmaceutical companies including Sanofi, LEO Pharma, Yakult Honsha Co., Ltd., Schwarz Pharma and BioNTech AG.

Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.

Dr. Vitt is currently a member of the supervisory board of Quattro Research GmbH, a software solutions provider for life science and chemistry applications, located in Planegg, Germany. He also is member of the advisory board of the venture capital fund “Wachstumsfond Bayern 2” managed by Bayern Kapital GmbH.

PROFILE

Skills

Entrepreneurial track record and leadership

Qualification

Co-Founder of 4SC AG, managing director and board member of several companies in the life-science industry

Experience

Transformation of R&D company to advanced clinical development stage and IPO on German stock exchange

Motivation

Leading companies to outstanding levels of excellence